Arumpac, Aileen A.
HRN: 19-38-35 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/20/2022
CO-AMOXICLAV 625MG (TAB)
06/20/2022
06/27/2022
PO
625mg
BID X 7 Days
S/P VBAC; UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes